A phase I dose escalation trial of AXP107-11, a novel multi-component crystalline form of genistein, in combination with gemcitabine in chemotherapy-naive patients with unresectable pancreatic cancer
- DOI
- 10.1016/j.pan.2016.05.002
- Published
- 2016-07
- Container
- Pancreatology
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.pan.2016.05.002,
title = {A phase I dose escalation trial of AXP107-11, a novel multi-component crystalline form of genistein, in combination with gemcitabine in chemotherapy-naive patients with unresectable pancreatic cancer},
author = {Johannes-Matthias Löhr and Masoud Karimi and Brigitta Omazic and Nikolaos Kartalis and Caroline Sabine Verbeke and Anders Berkenstam and Jan-Erik Frödin},
year = {2016},
journal = {Pancreatology},
doi = {10.1016/j.pan.2016.05.002},
url = {https://doi.org/10.1016/j.pan.2016.05.002}
}RIS
TY - JOUR TI - A phase I dose escalation trial of AXP107-11, a novel multi-component crystalline form of genistein, in combination with gemcitabine in chemotherapy-naive patients with unresectable pancreatic cancer AU - Johannes-Matthias Löhr AU - Masoud Karimi AU - Brigitta Omazic AU - Nikolaos Kartalis AU - Caroline Sabine Verbeke AU - Anders Berkenstam AU - Jan-Erik Frödin PY - 2016 JO - Pancreatology DO - 10.1016/j.pan.2016.05.002 UR - https://doi.org/10.1016/j.pan.2016.05.002 ER -
APA
Löhr, J., Karimi, M., Omazic, B., Kartalis, N., Verbeke, C. S., Berkenstam, A., & Frödin, J. (2016). A phase I dose escalation trial of AXP107-11, a novel multi-component crystalline form of genistein, in combination with gemcitabine in chemotherapy-naive patients with unresectable pancreatic cancer. Pancreatology. https://doi.org/10.1016/j.pan.2016.05.002
Source records
- crossref · retrieved 2026-09-27T07:26:11.702Z